Why the study?
Does perindopril/indapamide and/or intensive glucose control reduce macrovascular and microvascular disease in high-risk individuals with Type 2 diabetes?
Does perindopril/indapamide and/or intensive glucose control reduce macrovascular and microvascular disease in high-risk individuals with Type 2 diabetes?
The ADVANCE trial successfully recruited a large, diverse cohort of high-risk patients with Type 2 diabetes to evaluate the effects of blood pressure lowering and intensive glucose control on vascular outcomes.
Answers are grounded in this paper and cite their sources.
Enables evaluation of combined BP-lowering and glucose strategies on vascular outcomes in high-risk T2D; extends prior evidence with a large multinational cohort.
AIMS: The primary aim of ADVANCE is to determine the effects on macrovascular and microvascular disease of blood pressure lowering (with an ACE inhibitor-diuretic combination), irrespective of initial blood pressure level; and of intensive glucose lowering, in high-risk individuals with Type 2 diabetes. METHODS: The study is a 2 x 2 factorial randomized controlled trial. Following 6 weeks on active perindopril-indapamide combination, eligible participants were randomized to perindopril/indapamide (initially 2.0/0.625 mg daily, increasing to 4.0/1.25 mg daily after 3 months) or matching placebo; and to an intensive gliclazide MR-based glucose control regimen aiming for a haemoglobin A1c (HbA1c) value of 6.5% or lower, or local standard therapy. The study is being conducted in 215 centres in 20 countries within Australasia, Asia, Europe and North America. RESULTS: Recruitment commenced in June 2001 and was completed in March 2003, with the inclusion of 11,140 randomized participants. Fifty-seven per cent of participants are male and the mean age at baseline was 66 years. On average, the diagnosis of diabetes was made 8 years before study entry. At baseline 32 and 10% of patients had a history of macrovascular and microvascular disease, respectively. The mean blood pressure at baseline was 145/81 mmHg; the mean HbA1c concentration was 7.5%. While blood pressure and HbA1c values were broadly similar, certain characteristics of randomized participants varied between countries. CONCLUSIONS: With successful worldwide recruitment completed, ADVANCE should provide reliable and broadly generalizable results on the effects of routine blood pressure lowering and intensive glucose control in high-risk individuals with Type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
A 2005 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: